Lv51
940 积分 2022-07-17 加入
Targeting both death and paracaspase domains of MALT1 with antisense oligonucleotides overcomes resistance to immune-checkpoint inhibitors
7天前
已完结
MALT1 Inhibitors and Degraders: Strategies for NF-κB-Driven Malignancies
7天前
已完结
A pH-sensitive liposome formulation of a peptidomimetic-Dox conjugate for targeting HER2 + cancer
18天前
已完结
225Ac-PSMA-617 Augmentation in High-Risk mCRPC Undergoing 177Lu-PSMA-617 Radioligand Therapy
1个月前
已完结
Recent developments in pharmaceutical salts: FDA approvals from 2015 to 2019
1个月前
已完结
VIR-2218 (elebsiran) plus pegylated interferon-alfa-2a in participants with chronic hepatitis B virus infection: a phase 2 study
1个月前
已完结
OS-030 Efficacy and safety of xalnesiran with and without an immunomodulator in virologically suppressed participants with chronic hepatitis B: end of study results from the phase 2, randomized, controlled, adaptive, open-label platform study (PIRANGA)
1个月前
已完结
Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study
1个月前
已完结
HER2 Activating Mutations in Estrogen Receptor Positive Breast Cancer
2个月前
已完结
A Phase II Study of Neoadjuvant Opnurasib KRAS G12C Inhibitor in Patients With Surgically Resectable Non-Small Cell Lung Cancer (CCTG IND.242A): A Substudy of the IND.242 Platform Master Protocol
2个月前
已完结
皖公网安备34019202002308
